Affordable Access

Publisher Website

Varespladib.

Type
Published Article
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
Publication Date
Volume
11
Issue
2
Pages
137–143
Identifiers
DOI: 10.2165/11533650-000000000-00000
PMID: 21446779
Source
Medline

Abstract

Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. Varespladib acts by inhibiting secretory phospholipase A2 (sPLA2) and the drug is currently being evaluated in approximately 6500 patients with acute coronary syndromes receiving atorvastatin in the placebo-controlled VISTA 16 (NCT01130246) trial being conducted in North America and Europe. This review discusses the development history and scientific profile of this new compound.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments